SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-24-013384
Filing Date
2024-02-09
Accepted
2024-02-09 17:15:35
Documents
14
Period of Report
2024-02-08
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K evok-20240208.htm   iXBRL 8-K 56877
2 EX-1.1 evok-ex1_1.htm EX-1.1 394605
3 EX-99.1 evok-ex99_1.htm EX-99.1 23538
  Complete submission text file 0000950170-24-013384.txt   662915

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT evok-20240208.xsd EX-101.SCH 26089
15 EXTRACTED XBRL INSTANCE DOCUMENT evok-20240208_htm.xml XML 4533
Mailing Address 420 STEVENS AVENUE SUITE 370 SOLANA BEACH CA 92075
Business Address 420 STEVENS AVENUE SUITE 370 SOLANA BEACH CA 92075 858-345-1494
Evoke Pharma Inc (Filer) CIK: 0001403708 (see all company filings)

IRS No.: 208447886 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36075 | Film No.: 24616172
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)